- MDBZP
- Methylenedioxybenzylpiperazine
- MDBP
- 3,4-MDBP
- 1-[(2H-1,3-Benzodioxol-5-yl)methyl]piperazine
- 1-(1,3-Benzodioxol-5-ylmethyl)piperazine
Staack, RF; Maurer, HH. Metabolism of designer drugs of abuse Curr. Drug Metab., 1 Jun 2005, 6 (3), 259–274. 104 kB. https://doi.org/10.2174/1389200054021825 #MDBP
Maurer, HH. Mass spectra of select benzyl- and phenyl- piperazine designer drugs Microgram J., 1 Jan 2004, 2 (1–4), 22–26. 326 kB. MS
Clark, CR; DeRuiter, J. Analytical and synthetic studies on designer drugs of the piperazine class, US DOJ, 1 Dec 2014. 15.6 MB. #3,4-MDBP MS
Arbo, MD; Bastos, ML; Carmo, HF. Piperazine compounds as drugs of abuse Drug Alcohol Depend., 1 May 2012, 122 (3), 174-185. 523 kB. https://doi.org/10.1016/j.drugalcdep.2011.10.007
Uchiyama, N; Kikura-Hanajiri, R; Hakamatsuka, T. A phenethylamine derivative 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(3,4-methylenedioxyphenyl)methyl]ethanamine (25I-NB34MD) and a piperazine derivative 1-(3,4-difluoromethylenedioxybenzyl)piperazine (DF-MDBP), newly detected in illicit products Forensic Toxicol., 1 Jan 2016, 34 (1), 166–173. 1.0 MB. https://doi.org/10.1007/s11419-015-0304-7 LC,MS,NMR,UV
Takahashi, M; Nagashima, M; Suzuki, J; Seto, T; Yasuda, I; Yoshida, T. Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry Talanta, 15 Feb 2009, 77 (4), 1245–1272. 1.2 MB. https://doi.org/10.1016/j.talanta.2008.07.062 #MDBZP GC,LC,MS,UV
Nagashima, M; Seto, T; Takahashi, M; Suzuki, J; Yasuda, I. Spectrum data of the 3rd Governor-designated drugs and the analyses of uncontrolled drugs purchased Apr. 2005 – Mar. 2006 Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2006, 57 109–113. 394 kB. #MDBZP LC,NMR,IR,UV
Kikura-Hanajiri, R; Kawamura, M; Uchiyama, N; Ogata, J; Kamakura, H; Saisho, K; Goda, Y. Analytical data of designated substances (shitei-yakubutsu) controlled by the pharmaceutical affairs law in Japan, Part I: GC-MS and LC-MS Yakugaku Zasshi, 1 Jun 2008, 128 (6), 971–979. 1.4 MB. https://doi.org/10.1248/yakushi.128.971 #MDBP, piperonyl piperazine Incorrect structures drawn. Corrected structures in errata page at end. GC,LC,MS,UV
Uchiyama, N; Kawamura, M; Kamakura, H; Kikura-Hanajiri, R; Goda, Y. Analytical data of designated substances (shitei-yakubutsu) controlled by the pharmaceutical affairs law in Japan, Part II: Color test and TLC Yakugaku Zasshi, 1 Jan 2008, 128 (6), 981–987. 406 kB. https://doi.org/10.1248/yakushi.128.981 #MDBP TLC
Maurer, HH; Kraemer, T; Springer, D; Staack, RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (Ecstasy), piperazine, and pyrrolidinophenone types. A synopsis Ther. Drug Monit., 1 Apr 2004, 26 (2), 127–131. 121 kB.
Elliott, S. Current awareness of piperazines: pharmacology and toxicology Drug Test. Anal., 1 Jul 2011, 3 (7–8), 430–438. 148 kB. https://doi.org/10.1002/dta.307 #MDBZP